Introduction
============

Erectile dysfunction (ED) is the most frequently treated sexual dysfunction in men worldwide, and is defined as the recurrent or consistent inability to obtain and/or maintain an erection sufficient for satisfactory sexual performance ([@r1]). ED is seen in 15% of men 40--50 years old, 45% of men in their 60s, and 70% of men over 70 ([@r2],[@r3]). Over the past decade, an association between ED and cardiovascular disease (CVD) has been identified. While causality remains difficult to establish, ED may be an indicator of systemic disease, with both ED and CVD stemming from a common etiology. A better understanding of this association is warranted in order to properly counsel, screen, and treat patients presenting with ED.

Shared risk factors
===================

Several studies have demonstrated that common CVD risk factors are also risk factors for ED, including age, hypertension, diabetes, insulin resistance, smoking, increased body mass index (BMI), cholesterol, and decreased levels of high-density lipoprotein (HDL) cholesterol ([@r4]). In a large, prospective study, Fung *et al.* assessed seven classic CVD risk factors in male subjects and subsequently evaluated these men for ED 25 years later. Mean age, BMI, cholesterol, and triglycerides were all significantly associated with an increased risk of ED ([@r5]). A review of the Massachusetts Male Aging Study (MMAS) revealed that, after adjusting for age, a higher probability of ED correlated with a history of prior heart disease, hypertension, and diabetes ([@r6]). A follow-up study revealed that cigarette smoking almost doubled the likelihood of moderate or complete ED ([@r7]).

In obese men with a sedentary lifestyle, a significantly higher incidence of ED is observed than in normal men ([@r8]). Obesity also increases the risk of ED as a function of BMI. A multivariate analysis performed in a cohort study of 22,086 American men found that, compared to men with BMI \<25 kg/m^2^, those with a BMI of 25--26.9 kg/m^2^ had a 19% increased risk of developing ED, while those with BMI 27--29.9 kg/m^2^ had a 33% increased risk of developing ED ([@r9]).

The link between ED and another known CVD risk factor, diabetes mellitus, is also strong. Males with both type 1 and type 2 diabetes are at increased risk of ED when compared with non-diabetic men ([@r10]). The prevalence of ED in diabetic males ranges from 35--90% ([@r11]). Kalter-Leibovici *et al.* observed severe ED in nearly one third of men with diabetes and noted that ED worsened in severity with both advancing age and diabetes duration ([@r12]).

Links to CVD
============

A study of 300 men with angiographically documented coronary artery disease (CAD) found that 49% suffered from ED. The study, by Montorsi *et al.*, utilized the validated International Index of Erectile Function (IIEF) to assess ED severity in study subjects ([@r13]). A prospective study by Vlachopoulos *et al.* examined the incidence of asymptomatic CAD in patients with non-psychogenic, non-hormonal, vasculogenic ED. Ultimately, 19% of subjects were found to have angiographically-documented, but clinically asymptomatic CAD ([@r14]). Both studies found that ED symptoms preceded CAD by a significant time period. In the Vlachopoulos study, onset of symptomatic ED occurred 25 months prior to the discovery of silent CAD ([@r14]). Montorsi's subjects experienced ED symptoms an average of 39 months prior to the onset of CAD symptoms ([@r13]). Studies such as these support the conclusion that patients with ED may be suffering from a more significant, systemic process, and that ED may be a useful predictor of CVD.

The risk of all CV events, myocardial infarction, cerebrovascular events, and all-cause mortality were elevated in men with ED in several meta-analyses ([@r15],[@r16]). These studies support the hypothesis that ED is a silent marker for CVD. Ponholzer *et al.* calculated the 10-year risk of developing CVD in men with ED using the Framingham Risk Score (FRS), and reported that men with moderate to severe ED had a 43% and 65% increased relative risk for developing coronary heart disease or stroke, respectively ([@r17]). One study evaluated ED's role in disease prediction beyond the FRS. In 2010, Araujo *et al.* further evaluated data from the MMAS and found that ED was indeed associated with a higher incidence of CAD, but that it did not predict who would develop future CAD better than established risk factors and the FRS ([@r18]). Contrary to this, the Princeton III Consensus Conference suggested that ED itself is an independent marker of increased risk for CVD, CAD, stroke, and all-cause mortality. This consensus panel considered a man with organic ED to be at increased CVD risk until further evaluation suggested otherwise and provided guidance on CV risk screening and stratification ([@r19]).

A common pathophysiology for ED and CVD
=======================================

To better understand the link between ED and CVD, an understanding of the physiology of erection is useful. Erection results from coordinated communication of hormonal, neural, and vascular systems as well as psychological inputs. Sensory input from receptors in the skin, glans, urethra, and corporat cavernosa travel via the dorsal nerve of the penis, and later the pudendal nerve, to S2--S4 nerve roots. Interaction with the thalamus and sensory cortex leads to parasympathetic activation and release of nitric oxide (NO) from the cavernous nerves and endothelial cells. NO activates guanylyl cyclase, which catalyzes the formation of cyclic guanosine monophosphate (cGMP). Protein kinase G is activated by cGMP and leads to phosphorylation of potassium and calcium channels, cellular hyperpolarization, reduced intracellular calcium, and smooth muscle relaxation. This smooth muscle relaxation, along with decreased peripheral arteriolar resistance promotes blood inflow into the corporal tissues. In addition, adenosine, prostaglandins, and calcitonin gene-related peptides may activate cyclic adenosine monophosphate (cAMP), a similar mediator of smooth muscle relaxation ([@r20]). cGMP and cAMP are later degraded by phosphodiesterase type 5 (PDE5) and PDE4, respectively ([@r21]).

The discovery of NO as a signaling molecule and its part in the cascade that ultimately leads to an erection led to further exploration of the role of endothelial dysfunction in ED. Endothelial integrity is crucial to this process, and endothelial dysfunction is thought to be a common denominator between ED and CVD ([@r22]). Initial impairments to the endothelium-dependent vasodilation in penile tissues may lead to late structural changes, penile artery atherosclerosis, and flow-limiting stenosis similar to that seen in CAD ([@r23]).

The artery size hypothesis
==========================

Montorsi *et al.* introduced the artery size hypothesis as a pathophysiologic mechanism to address the association between ED and CVD. The study proposed that, in cases of systemic atherosclerosis, all major vascular beds should be affected to the same extent. Symptoms, however, do not manifest equally at different points in the system, likely due to larger vessels being able to tolerate the same amount of obstruction better than smaller vessels. Given the smaller size of the penile vasculature (1--2 mm) compared to coronary vasculature (3--4 mm), ED is more likely to manifest earlier than CAD. This study was one of the first to propose that ED and CAD are different manifestations of the same systemic condition. It was also one of the first studies to introduce ED as a harbinger of CAD ([@r24]). A subsequent study supported this finding, suggesting that ED occurs prior to cardiac symptoms in virtually all patients with chronic coronary syndrome with a time interval of approximately 3 years. Those with acute coronary syndrome had a much lower prevalence of sexual dysfunction, although as the extent of CAD increased in these patients, so did the rate of ED ([@r25]). A study by Rogers *et al.* provided further support for the relationship between vessel size and symptoms, reporting that the degree of stenosis within the internal pudendal arteries (52--65%) was similar to stenosis found in coronary arteries of patients with ED unresponsive to PDE5 inhibitors ([@r26]).

Chang *et al.* characterized the phenotypes of coronary vasculature in CAD patients with and without ED. Thirty males with ED (average duration of 2.7 years) and asymptomatic CAD were compared to age-matched controls with angina pectoris and no ED. Subjects with ED and asymptomatic CAD had more coronary vessels involved than the angina group and were found to have a greater number of type C lesions (American Heart Association/American College of Cardiology grading system), which represent lesions with a chance of successful dilation of \<60% and/or a high risk of abrupt complete vessel stenosis ([@r27]).

One limitation of the artery size hypothesis is the fact that not all cases of vasculogenic ED are caused solely by penile atherosclerosis. In fact, while evaluating a small cohort of 31 men over 45 years old undergoing autopsy, Ponholzer *et al.* found that clinically significant penile atherosclerosis was relatively rare (12.9%) compared to coronary (87%) or internal iliac vessel disease (77%) ([@r28]). Though this study was relatively small, it supports the conclusion that atherosclerotic lesions do not form uniformly in all vascular areas. It is likely that other factors such as microscopic endothelial damage and alterations of the NO-cGMP pathway may play a role as well.

The role of inflammation in CVD and ED
======================================

Several studies have suggested that chronic inflammation and circulating inflammatory markers affect systemic endothelial function. Chronic inflammation may, therefore, represent a link between ED and CVD. ED onset and severity are associated with increased expression of markers of inflammation. Markers and mediators such as C-reactive protein (CRP), intercellular adhesion molecule 1, interleukin (IL)-6, IL-10, IL-1B, and tumor necrosis factor alpha (TNF-α) were found to be expressed at higher levels in patients with ED. In addition, endothelial and prothrombotic factors such as von Willebrand factor (vWF), tissue plasminogen activator (tPA), plasminogen activator inhibitor 1 (PAI-1), and fibrinogen are also expressed at higher levels in ED patients \[reviewed in ([@r29])\]. Vlachopoulos found that levels of circulating inflammatory markers were indeed elevated in men with ED in both the presence and absence of CAD. Marker levels were similar in patients with ED alone compared to patients with CAD alone, suggesting that ED and CAD are equivalent with respect to activation of inflammatory and prothrombotic pathways. The presence of ED is also thought to add to the negative impact of inflammation in patients with CAD ([@r30]).

Hypogonadism in CVD and ED
==========================

Androgens play an important role in both penile and vascular health, with cellular targets located in both endothelial and smooth muscle cells. Within the vasculature, androgens promote endothelial cell survival, inhibit proliferation and intimal migration of vascular smooth muscle cells, and reduce endothelial expression of pro-inflammatory markers. Within the penis, low androgen levels are associated with apoptosis of endothelial and smooth muscle cells as well as with pathologic structural remodeling ([@r31]).

Several studies have suggested a link between low testosterone and CVD. Lee *et al.* found that testosterone levels were negatively correlated with Framingham risk scores in patients with sexual dysfunction ([@r32]). Cao *et al.* studied a population of elderly males with CAD and found that compared to controls, these men had significantly lower levels of both total and free testosterone, as well as decreased expression of androgen receptors ([@r33]). Low androgen levels have also been associated with an increased risk of cardiovascular death ([@r34]). Malkin *et al.* observed that androgen deficiency in men with CAD was associated with increased all-cause and vascular mortality ([@r35]). Corona *et al.* reported that low testosterone levels are significantly associated with cardiovascular death in patients with ED ([@r34]).

Testosterone's role in CVD
==========================

Our knowledge of the intersection between testosterone and cardiovascular risk continues to evolve. Animal studies suggest that testosterone plays a role in coronary artery vasodilation ([@r36]-[@r38]). Recently, multiple randomized, placebo-controlled trials have shown that testosterone therapy improves myocardial ischemia in men with CAD ([@r39]-[@r41]). English *et al.* observed that testosterone therapy decreased exercised-induced myocardial ischemia in men with stable angina. In addition, a significant decrease in pain perception, as well as role limitation due to physical problems was noted in the testosterone therapy group ([@r39]). Similarly, Rosano *et al.* demonstrated an increased time to 1 mm ST-segment depression in men with CAD receiving intravenous testosterone prior to exercise stress testing ([@r40]). It is important to note that these changes were seen with both transdermal and intravenous testosterone formulations.

The mechanism by which testosterone affects vasomotor response remains under investigation. Webb *et al.* demonstrated that physiologic levels of intracoronary testosterone led to increased coronary artery dilation as well as increased coronary blood flow in men with established CAD via an endothelium-independent pathway ([@r42]). Additional studies suggest that the most likely mechanism of action of testosterone on vascular smooth muscle is via modulation of non-ATP-sensitive potassium ion channels, calcium-activated potassium ion channels, voltage-sensitive potassium ion channels, and finally L-type calcium ion channels ([@r43]).

Testosterone is also thought to play a role in regulating ventricular repolarization. Prolongation of heart rate corrected QT interval (QTc), an accepted measure of ventricular repolarization, is associated with increased incidence of ventricular arrhythmias, including torsades de pointes ([@r44]). Charbit *et al.* examined the QTc interval in hypogonadal men and observed a significant negative correlation between QTc length and total testosterone levels, a finding echoed by van Noord *et al.* ([@r45],[@r46]). Charbit *et al.* also examined the effects of a single intramuscular injection of testosterone enanthate on QTc and found that testosterone therapy shortened QTc. Its greatest effect was noted 2 days after administration, with statistically significant differences noted up to 4--6 weeks after administration ([@r45]).

An inverse correlation between testosterone levels and carotid intima-media thickness (IMT) has been demonstrated by several studies ([@r47]-[@r49]). IMT is considered a marker for preclinical atherosclerosis and is generally considered a risk factor for adverse cardiovascular events ([@r50],[@r51]). The mechanism of action by which testosterone affects IMT remains unclear, but current data suggests endogenous testosterone may be protective against the development of atherosclerosis.

In addition to direct effects on the coronary vasculature, testosterone replacement may further affect CVD risk by modulating known CVD risk factors. Kalinchenko *et al.* showed that intramuscular testosterone therapy led to significant improvements in the BMIs of men with metabolic syndrome (MetS) ([@r52]). Corona *et al.* also revealed a reduction in fat mass after testosterone replacement therapy. Additionally, this same analysis revealed that testosterone therapy lowered hemoglobin A1c and fasting plasma glucose ([@r53]). Whitsel *et al.* demonstrated that intramuscular testosterone led to a reduction in both HDL and LDL, although studies published by Haddad and Isidori reported conflicting results ([@r54]-[@r56]).

A study done by Basaria *et al.* in 2010 was stopped prematurely due to an increased rate of adverse cardiovascular events observed in men receiving transdermal testosterone, raising concern that testosterone may carry significant cardiovascular risk ([@r57]). However, several limitations in this study have been pointed out. For example, the mean age of the study population was 74 years, with a very high percentage of the population suffering from serious chronic illnesses including diabetes, dyslipidemia, obesity, hypertension, and pre-existing heart disease. Significant limitations in mobility existed at baseline, as the purpose of this study was to measure improvement in physical strength. A number of adverse events reported may have been minor phenomena and not true cardiac events. Finally the sample size was thought to be relatively small. Several meta-analyses have investigated the association between testosterone therapy and adverse events. Calof *et al.* analyzed 19 randomized placebo controlled trials. No significant difference in rate of cardiovascular events was noted. An increased combined incidence of all prostate related adverse events was noted. These included combined prostate events such as all incidents of prostate biopsies, PSA \>4 ng/mL or an increase of 1.5 ng/mL during the study, prostate cancer, acute urinary frequency, and an increase in international prostate symptom score. Of note, none of these individual adverse events were significantly different than those observed in the placebo group. A significant rise in hematocrit \>50% was observed in the testosterone group. Finally, skin irritation at the site of testosterone application was noted in studies using topical testosterone ([@r58]). A second analysis by Haddad *et al.* also failed to find a statistically significant difference in adverse cardiovascular events ([@r56]). Fernández-Balsells *et al.* analyzed 51 studies which included men receiving testosterone therapy for over 3 months. Again, a significant increase in hemoglobin and hematocrit levels was seen in the therapy group compared to those receiving placebo. No difference was found when comparing rate of death, MI, coronary revascularization procedures, or arrhythmias. No difference was seen in rates of prostate cancer, need for prostate biopsy, international prostate symptom score, increase in PSA, or combined prostate related adverse events ([@r59]).

MetS
====

MetS, now considered an important public health threat, is a constellation of several cardiovascular risk factors associated with a 2-fold increase of a 5- to 10-year risk of CVD. MetS is characterized by the presence or treatment of any three of the following: abdominal obesity (waist \>94 cm), triglycerides \>150 mg/dL, blood pressure \>130/85 mmHg, fasting glucose \>100 mg/dL, and HDL \<40 mg/dL ([@r60]). Low levels of androgens are strongly associated with MetS and its components ([@r61]). In a study of men with low serum testosterone, García-Cruz *et al.* found that MetS was associated with significantly lower IIEF scores. Incidence of moderate to severe ED was higher among subjects with MetS versus those without. Severity of ED was found to be associated with severity of MetS, with an increased mean number of MetS components seen as ED severity increased. Multivariate analysis revealed that moderate and severe ED were the variables associated with the highest odds of MetS ([@r62]).

Yassin *et al.* followed 261 patients diagnosed with late onset hypogonadism and ED treated with testosterone undecanoate (TU). The mean duration of treatment was more than 4 years. The study assessed parameters affected by MetS, including body weight, waist circumference, BMI, total cholesterol, LDL, HDL, triglycerides, glucose, hemoglobin A1c, and blood pressure. Significant improvements in obesity parameters (BMI and waist circumference) were observed, along with a decrease in total cholesterol, LDL, triglycerides, fasting blood glucose, hemoglobin A1c, and blood pressure over the course of the study. Health related quality of life was significantly improved after testosterone therapy, with sustained improvement in erectile function and muscle and joint pain ([@r63]).

Screening for CVD
=================

Given the evidence supporting a link between ED, CVD, and mortality, as well as the fact that ED may precede CV events by several years, it is recommended that men with ED be screened for CVD, with evaluation for related comorbidities where appropriate ([@r64]). However, controversy exists as to whether the presence ED improves the prediction of CVD beyond traditional risk factors. Araujo *et al.* found that ED did not improve risk assessment above traditional methods such as FRS ([@r18]). The joint 2013 American College of Cardiology/American Heart Association guideline on assessment of cardiovascular risk mentions ED as being investigated and considered as a risk predictor, but its contribution is awaiting further consideration ([@r65]). In 2012, the Princeton III Consensus Conference aimed to focus on the predictive value of vasculogenic ED in assigning cardiovascular risk to men of all ages. The consensus recognized ED to be, in itself, an independent marker of increased risk for CVD, CAD, stroke and all-cause mortality. The panel considered all men over 30 years of age with ED to be at an increased risk for CVD, recommending thorough noninvasive and, when indicated, invasive evaluation of CVD status ([@r19]).

While ED's role as a novel trigger for further testing may be under investigation, any sexual dysfunction evaluation is an opportunity for physicians to gather information regarding each patient's overall health profile, including any evidence of co-existing cardiac risk factors, such as hypertension, hyperlipidemia, diabetes, and smoking. Evaluation for obesity, including BMI as well as waist and hip measurements, should be considered. Validated questionnaires may also be utilized to assess the severity of sexual dysfunction \[i.e., Sexual Health Inventory for Men (SHIM), IIEF\] as well as assess for hypogonadism \[Androgen Deficiency in the Aging Male (ADAM or qADAM)\].

Initial laboratory testing includes assessment of the hypothalamic-pituitary-gonadal axis, lipid status, and sugar metabolism. The International Conference on Sexual Medicine (ICSM) recommends testing fasting blood glucose, lipid levels, and gender-specific hormones during the evaluation of sexual dysfunction in men ([@r66]). Hemoglobin A1c is strongly associated with ED and may be considered in lieu of fasting blood glucose or in men with known diabetes ([@r67]). Evaluation of the hypothalamic-pituitary-gonadal-axis should include determination of testosterone, free testosterone, sex hormone-binding globulin, prolactin, luteinizing hormone, and follicle-stimulating hormone levels. Recommendations for routine hormonal blood tests remain controversial, but are supported by several groups such as the Princeton III Consensus Conference, British Society for Sexual Medicine, and the International Society for Sexual Medicine ([@r19]).

Patients should be risk stratified during their initial physician visit. The Princeton III Consensus Conference equated sexual activity to walking one mile on a flat surface in twenty minutes or climbing 2 flights of stairs in 10 seconds. Low-risk patients are those that can perform exercise of modest intensity without symptoms, and do not generally require additional cardiovascular workup prior to ED treatment. High-risk patients are those with cardiac conditions severe or unstable enough to pose a significant risk with sexual activity. Common profiles include unstable angina pectoris, uncontrolled hypertension, congestive heart failure (NYHA class IV), high risk arrhythmias (exercise induced ventricular tachycardia, implanted internal cardioverter defibrillator with frequent shocks, poorly controlled atrial fibrillation), obstructive hypertrophic cardiomyopathy, and moderate to severe valvular disease such as aortic stenosis. High-risk individuals should be referred to a cardiologist for further evaluation prior to initiation of treatment for ED and/or sexual activity. Patients considered at intermediate risk, such as those with mild or moderate angina pectoris, past MI (2--8 weeks) without intervention, congestive heart failure (NYHA class III), and non-cardiac sequelae of atherosclerotic disease (TIA, stroke, PAD), should be further evaluated with an exercise or chemical stress tests. Sexual activity is equivalent to 4 minutes of the Bruce treadmill protocol. These patients may then be categorized as low or high risk, and may proceed with treatment or further evaluation when appropriate ([@r19]).

Conclusions
===========

ED is the most common male sexual dysfunction. Growing evidence has established that ED shares many risk factors with systemic conditions including CVD and the MetS. ED has been linked to CVD and is considered a potential harbinger of future cardiovascular events. Given this relationship, each encounter for ED should be viewed by healthcare providers as an opportunity to screen for CVD and other comorbid conditions that can significantly affect a man's overall health. Proper referral for additional testing should be pursued when warranted as well. While universally accepted screening guidelines do not yet exist, expert panel suggestions such as the Princeton III Consensus Conference provide an initial risk stratification method for men with ED. Further research on the relationship between ED, CVD and MetS is required. As our understanding of this link evolves, so should our approach to evaluating and treating patients presenting with ED.
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